Business Context and Reporting Period
Sol-Gel Technologies Ltd. (Nasdaq: SLGL) is an Israeli dermatology company focused on developing topical treatments for skin conditions. The filing is an Annual Report on Form 20-F for the fiscal year ended December 31, 2025. The company operates with two FDA-approved products, Twyneo (acne) and Epsolay (rosacea), and a pipeline of investigational candidates, primarily SGT-610 (Gorlin syndrome) and SGT-210 (EGFR inhibition platform).
Key strategic developments in 2025 included the sale of U.S. rights for Twyneo and Epsolay to Mayne Pharma for $16 million following the termination of the Galderma license, and the advancement of the Phase 3 clinical trial for SGT-610.
Key Financial Metrics
| Metric (in thousands USD) | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Revenues | $1,554 | $11,538 | $19,388 |
| Net Loss | $(27,238) | $(10,580) | $(6,127) |
| Operating Loss | $(29,305) | $(12,014) | $(7,538) |
| R&D Expenses | $23,541 | $17,803 | $22,804 |
| G&A Expenses | $7,373 | $5,749 | $4,176 |
| Cash & Equivalents (Year End) | $7,513 | $19,489 | $11,033 |
| Total Assets | $35,846 | $29,917 | $29,917 |
| Accumulated Deficit | $(220,303) | $(230,883) | $(237,010) |
Liquidity: As of December 31, 2025, the company held $12.4 million in cash, cash equivalents, bank deposits, and marketable securities. Management estimates these resources will fund operations into the first quarter of 2027.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 68% year-over-year from $11.5 million in 2024 to $19.4 million in 2025. This was driven primarily by $16 million in proceeds from the sale of U.S. rights to Mayne Pharma and milestone payments from Searchlight.
- Expense Fluctuations: R&D expenses rose 28% to $22.8 million, attributed to a $5 million increase in API manufacturing costs for SGT-610 and Phase 3 trial advancements. Conversely, G&A expenses decreased 27% to $4.2 million due to cost-saving measures and reduced payroll.
- Loss Reduction: The net loss narrowed significantly to $6.1 million in 2025 compared to $10.6 million in 2024, reflecting the revenue spike from asset sales.
- Strategic Shift: The company exited the U.S. commercialization of Twyneo and Epsolay directly, transferring rights to Mayne Pharma, shifting its focus to licensing and royalty models in other territories.
Guidance, Outlook, and Risks
Outlook: The company expects to report top-line results for the SGT-610 Phase 3 trial in the fourth quarter of 2026. Management anticipates continuing to incur net losses as it invests in clinical development and seeks regulatory approvals.
Going Concern: The independent auditor has included an explanatory paragraph regarding "substantial doubt" about the company's ability to continue as a going concern due to recurring losses and negative operating cash flows. The company will require additional financing to sustain operations beyond early 2027.
Key Risks:
- Geopolitical Instability: Ongoing conflicts in the Middle East (Israel, Iran, Hezbollah) pose risks to operations, supply chains, and employee safety, though no material impact was recorded in 2025.
- Regulatory Uncertainty: Success depends on the Phase 3 trial results for SGT-610 and regulatory approvals for Twyneo and Epsolay in international markets (e.g., Canada, China).
- Capital Needs: Failure to raise additional capital could force the curtailment of operations or dilution of shareholders.
- PFIC Status: The company believes it was a Passive Foreign Investment Company (PFIC) for 2025, which may have adverse tax consequences for U.S. holders.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $12.4 million cash balance to fund operations through Q1 2027 and the timeline for potential capital raises.
- SGT-610 Trial Status: Monitor patient enrollment progress and the timeline for the Q4 2026 top-line data readout, which is critical for future valuation.
- Licensee Performance: Assess the commercial performance of Twyneo and Epsolay by partners (Mayne, Searchlight, Beimei) to validate future royalty revenue streams.
- Geopolitical Exposure: Review updates on the security situation in Israel and its potential impact on manufacturing and clinical trial execution.
- Going Concern Mitigation: Evaluate management's specific plans for raising capital and the terms of any potential equity or debt financing.